# RETU Pyelonephritis Pathway

# Required testing prior to RETU admission

- Urinalysis
- Urine culture
- CBC, creatinine
- pregnancy test in women of childbearing age

# ED Evaluation

#### Not appropriate for RETU

- Hemodynamic instability
- AMS
- Pregnancy
- Immunocompromised patients
- · Significant comorbidities
- Bacteremia or Sepsis
- Acute renal failure
- Urinary tract anatomic abnormality (i.e. solitary kidney)

# **RETU Intake Evaluation**

(do not repeat testing if already done in ED

#### Exam Focus

- Abdominal
- Genitourinary

# Initial Testing

- Labs: Urinalysis, Urine Culture, CBC, Chem 7 (others as clinically indicated)
- Imaging: CT or US (if clinically indicated)

#### Monitoring

- •Monitor fever curve
- Monitor pain level

#### Consults

 ID consult as clinically indicated

# RETU Treatment / Evaluation


#### IV Antibiotics\*

- Ceftriaxone 1g q24h
- Cefepime 2g q12h
- Ciprofloxcin 400mg q12h
- Levofloxacin 750mg q24h

Transition to PO antibiotics

Ciprofloxacin 500mg BID
Levofloxacin 740mg daily
Bactrim DS 1 tab BID
Cefpodoxime 200mg BID

# Clinical improvement?



microbiology if available

# Treatment Adjuncts

- IV fluid
- 7ofran 4mg IV g4h PRN
- Reglan 10mg IV g6h PRN
- Tylenol 650mg PO g4h PRN
- Toradol 30mg IV a6h PRN
- Ibunrafen 800ma PO a8h

### Disposition Guidelines

## Discharge from RETU

- Stable vital signs
- Tolerating PO fluids and medications
- Resolutions or improvement of systemic symptoms
- WBC count nearly normal or improved

#### Admission to Hospital

- Continued T>101F
- Unstable vital signs or sepsis
- Inability to tolerate PO fluids and medications
- Abnormal imaging (i.e. emphysematous pyelo)